<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078710</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-ZS-3026</org_study_id>
    <nct_id>NCT05078710</nct_id>
  </id_info>
  <brief_title>Telitacicept in Primary APS Patients</brief_title>
  <official_title>A Pilot Study of Telitacicept Treatment in Primary APS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm pilot study in Peking Union Medical College Hospital. Telitacicept will&#xD;
      be added on traditional antithrombotic and immunosuppressive treatment in primary&#xD;
      antiphospholipid syndrome (APS) patients with three positive antiphospholipid antibodies&#xD;
      (aPL) and at least one extra-criteria manifestations, including thrombocytopenia, autoimmune&#xD;
      hemolytic anemia, aPL associated nephropathy, heart valvular disease, non-stroke neurological&#xD;
      manifestations. This study aims to evaluate the efficacy of Telitacicept in preventing&#xD;
      thrombosis and improving extra-criteria manifestations on high-risk APS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study started on July 2021 and will last 1.5 years. Primary APS patients with three&#xD;
      positive aPL and extra-criteria manifestations with be enrolled. This is a single-arm pilot&#xD;
      study. Telitacicept 160mg once a week for 24 weeks will be added on traditional&#xD;
      antithrombotic and immunosuppressive treatment. Patients will be followed on week 12 and week&#xD;
      24. The primary endpoint is new thrombotic event. The secondary endpoints are improvement of&#xD;
      extra-criteria manifestations, and titer change of aPL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>new thrombotic event</measure>
    <time_frame>24 weeks</time_frame>
    <description>any new thrombotic event during Telitacicept treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of thrombocytopenia during Telitacicept treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>elevated platelet counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of hemolytic anemia during Telitacicept treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>elevated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of aPL nephropathy during Telitacicept treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>decrease of proteinuria or creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of valve heart disease during Telitacicept treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>decrease of valve thickness or vegetation by echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of neurological manifestations during Telitacicept treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>MRI improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decrease of aPL titer during Telitacicept treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>titer change of lupus anticoagulant, anticardiolipin antibody and anti-β2 glycoprotein-I antibody</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anti Phospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Telitacicept arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telitacicept 160mg once a week for 24 week as an add-on treatment regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telitacicept</intervention_name>
    <description>160mg once a week for 24 weeks</description>
    <arm_group_label>Telitacicept arm</arm_group_label>
    <other_name>traditional antithrombotic and immunosuppressive treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  meet 2006 Sapporo classification criteria of APS;&#xD;
&#xD;
          -  diagnosis of primary APS, exclude other etiologies of thrombosis;&#xD;
&#xD;
          -  with three aPL medium-to-high titer positivity, namely lupus anticoagulant, anti&#xD;
             cardiolipin antibody, and anti-β2 glycoprotein antibody;&#xD;
&#xD;
          -  with at least one extra-criteria manifestations of APS, including thrombocytopenia,&#xD;
             hemolytic anemia, aPL nephropathy, valve heart disease and neurological&#xD;
             manifestations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  overlap with other connective tissue diseases, such as systemic lupus erythematosus;&#xD;
&#xD;
          -  during pregnancy;&#xD;
&#xD;
          -  can not follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiuliang Zhao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiuliang Zhao, M.D.</last_name>
    <phone>0086-13810103105</phone>
    <email>Jiuliang.zhao@cstar.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Can Huang, M.D.</last_name>
    <phone>0086-13426191948</phone>
    <email>huang_can@yeah.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiuliang Zhao, M.D.</last_name>
      <phone>0086-13810103105</phone>
      <email>Jiuliang.zhao@cstar.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti phospholipid syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

